▶️Fudan’s Wanyan Ruiyun on Huiminbao and the C-List: From Central Negotiation to Market Uptake and Insurance Innovation
Key topics covered in this C-List and Commercial Drug Catalog Masterclass Huiminbao Interview with Dr. Wanyan Ruiyun:
• New Negotiation Dynamics
What factors most influence commercial insurers’ coverage decisions and pricing recommendations for innovative drugs under the dual-list adjustment framework.
• Preparing for Central Negotiation
How manufacturers can get ready for China’s first-ever national-level negotiation with commercial insurers.
• Impact on Huiminbao Coverage and Drug Pricing
How the commercial innovative drug list is reshaping Huiminbao’s specialty drug offerings—and the potential for second-round negotiations, regional alliances, and pricing convergence across plans.
• Beyond Huiminbao: China’s Promising New Public-Private Payment Model
What new model is redefining public-private collaboration in China—and how might the commercial innovative drug list accelerate this next wave of innovation?
• Consumer Uptake & Delivery System Shifts
Emerging levers to boost consumer adoption, and how insurance innovation may reshape China’s drug distribution system.
• Gaps in China’s Regulatory Framework
What’s holding back commercial health insurance innovation in China—and what signals suggest change may be coming?
• NHSA’s “Innovation-Supporting” Commercial Insurer
A look into NHSA’s new designation—and how commercial insurers are responding. Will it foster sustainable “patient capital” to support China’s growing biopharma sector?
• A Rare Window into Policymaker Mindset
What stood out most: Dr. Wanyan offers a rare insider perspective on how Chinese policymakers think—how they weigh trade-offs, manage constraints, and shape policy with long-term strategic intent. Equally valuable are his insights into the practical hurdles of policy implementation—what slows execution, and why intentions don’t always translate into action.
About Dr. Wanyan Ruiyun
- Deputy Director, China Insurance and Social Security Research Center, Fudan University
- Former senior policy official at the China Insurance Regulatory Commission
- Prolific scholar and influential voice in shaping China’s insurance innovation and multi-pillar financing models
About Kelly Ke (Interviewer)
- Award-winning former Senior Advisor, Deloitte US Life Sciences Practice
- Founder, bizi LLC, an access intelligence consultancy
- Author, NRDL+ Executive Debrief—a widely followed China market access newsletter for global life sciences leaders
